Vyne Therapeutics Inc
VYNE0.560USD
+0.003+0.48%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
17.78M시가총액
손실P/E TTM
자세한 내용은 Vyne Therapeutics Inc 회사
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc 정보
종목 코드 VYNE
회사 이름Vyne Therapeutics Inc
상장일Jan 25, 2018
CEODomzalski (David)
직원 수13
유형Ordinary Share
회계 연도 종료Jan 25
주소685 Route 202/206 N., Suite 301
도시BRIDGEWATER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호08807
전화18007757936
웹사이트https://vynetherapeutics.com/
종목 코드 VYNE
상장일Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7858.00%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
51.16K
-3579.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
41.85K
-2448.00%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
104.92K
-7858.00%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
51.16K
-3579.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
41.85K
-2448.00%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
사업별USD
이름
수익
비율
Royalty revenues
501.00K
0.00%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Royalty revenues
501.00K
0.00%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
기타
88.75%
주주
주주
비율
Access Industries, Inc.
3.35%
Baker Bros. Advisors LP
2.56%
Delaware Street Capital, L.L.C.
2.09%
Acorn Capital Advisors, LLC
1.76%
Shay Capital LLC
1.48%
기타
88.75%
주주 유형
주주
비율
Hedge Fund
8.46%
Investment Advisor
3.54%
Corporation
3.35%
Investment Advisor/Hedge Fund
2.27%
Individual Investor
1.23%
Research Firm
0.45%
기타
80.70%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
88
4.85M
14.58%
-6.84M
2025Q3
84
8.51M
25.77%
-898.65K
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Access Industries, Inc.
1.12M
3.35%
--
--
Oct 15, 2025
Baker Bros. Advisors LP
851.35K
2.56%
+851.35K
--
Sep 30, 2025
Delaware Street Capital, L.L.C.
696.47K
2.09%
--
--
Sep 30, 2024
Acorn Capital Advisors, LLC
586.57K
1.76%
-150.00K
-20.36%
Sep 30, 2025
Shay Capital LLC
492.58K
1.48%
+492.58K
--
Sep 30, 2025
Acadian Asset Management LLC
446.41K
1.34%
+424.00K
+1891.32%
Sep 30, 2025
The Vanguard Group, Inc.
190.38K
0.57%
-305.91K
-61.64%
Sep 30, 2025
Ikarian Capital LLC
290.00K
0.87%
--
--
Sep 30, 2025
Two Sigma Investments, LP
277.39K
0.83%
+277.39K
--
Sep 30, 2025
Domzalski (David T)
152.86K
0.46%
-12.68K
-7.66%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
날짜
배당락일
유형
비율
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
